Please assess the completion status of the following clinical trial:

Trial Title: Study of BGB-A317 in Participants With Previously Treated Unresectable HCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Histologically confirmed HCC~2. Participants with Barcelona Clinic Liver Cancer (BCLC) Stage C, or BCLC stage B not amenable to locoregional therapy or relapsed after locoregional therapy, and not amenable to a curative treatment approach~3. Has received at least 1 line of systemic therapy for unresectable HCC~4. Has at least 1 measurable lesion as defined per RECIST v1.1~5. Child-Pugh score A~6. Easter Cooperative Oncology Group (ECOG) Performance Status ≤ 1~7. Adequate organ function~Key Exclusion Criteria:~1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC histology~2. Prior therapies targeting PD-1 or PD-L1~3. Has known brain or leptomeningeal metastasis~4. Tumor thrombus involving main trunk of portal vein or inferior vena cava~5. Loco-regional therapy to the liver within 4 weeks before enrollment~6. Medical history of interstitial lung disease, non-infectious pneumonitis or uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, or acute lung diseases~7. Has received:~   1. Within 28 days or 5 half-lives (whichever is shorter) of the first study drug administration: any chemotherapy, immunotherapy (eg, interleukin, interferon, thymoxin) or any investigational therapies~  2. Within 14 days of the first study drug administration: sorafenib, regorafenib, or any Chinese herbal medicine or Chinese patent medicines used to control cancer~8. Active autoimmune diseases or history of autoimmune diseases that may relapse~9. Participant with any condition requiring systemic treatment with either corticosteroids (\> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 14 days before study drug administration~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tislelizumab (Type: EXPERIMENTAL): 200 milligrams once every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).